Olaparib
FDA-approved product (capsule, oral), marketed as Lynparza.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 4 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Breast cancer
- Breast carcinoma
- Breast neoplasm
- Cancer
- Neoplasm
- Ovarian cancer
- Ovarian carcinoma
- Ovarian neoplasm
- Pancreatic carcinoma
- Pancreatic neoplasm
- Prostate cancer
- Prostate carcinoma
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Poly (adp-ribose) polymerase (parp) inhibitors
- FDA pharmacologic class
- Poly(ADP-Ribose) Polymerase Inhibitor FDA label ↗
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA, E. coli and K. pneumoniae. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA69.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli55.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae48.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- M. tuberculosis56.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Olaparib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- FurazolidoneExisting use: Other antiinfectives and antiseptics91.4% AI-predicted activityagainst M. tuberculosisLab records exist49 registered studies
- TriflupromazineExisting use: Psychosis90.6% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- ValdecoxibExisting use: Dysmenorrhea, Osteoarthritis, Rheumatic disease and 1 more88.6% AI-predicted activityagainst M. tuberculosisLab records exist31 registered studies
- CelecoxibExisting use: Ankylosing spondylitis, Cancer, Colorectal neoplasm and 15 more87.6% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- Dorzolamide HydrochlorideExisting use: Glaucoma, Ocular hypertension, Open-angle glaucoma86.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- MethazolamideExisting use: Glaucoma, Open-angle glaucoma85.6% AI-predicted activityagainst M. tuberculosisLab records exist11 registered studies
- AcetazolamideExisting use: Altitude sickness, Angle-closure glaucoma, Congestive heart failure and 5 more85.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- Trifluoperazine HydrochlorideExisting use: Anxiety disorder, Mental or behavioural disorder, Psychosis and 1 more84.6% AI-predicted activityagainst M. tuberculosis1 registered study
- TriclosanExisting use: Phenol and derivatives, Medicated dressings with antiinfectives84.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- NitrofurazoneExisting use: Eye infection, Leishmaniasis, Trypanosomiasis84.0% AI-predicted activityagainst M. tuberculosis8 registered studies
- BrinzolamideExisting use: Glaucoma, Ocular hypertension, Open-angle glaucoma83.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- ZonisamideExisting use: Epilepsy, Focal-onset seizure, Partial epilepsy and 1 more82.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Olaparib Dose Escalating Trial + Concurrent RT With or Without Cisplatin in Locally Advanced NSCLC
NCT01562210 · start 2012-04
Registered record
- Registry ID
- NCT01562210
- Conditions
- NSCLC
- Interventions
- Olaparib; Cisplatin; Radiation
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2012-04
- Completion
- 2020-03-13
- Enrolment
- 28
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionNSCLCInterventionOlaparib; Cisplatin; RadiationPhasePhase 1Registry statusCompletedTrial of ICM With or Without AZD2281 (Olaparib) in Patients With Advanced Pancreatic Cancer
NCT01296763 · start 2011-01
Registered record
- Registry ID
- NCT01296763
- Conditions
- Pancreatic Cancer
- Interventions
- Irinotecan; Cisplatin; Olaparib (for levels 1 and 5); Olaparib (for dose level 2); Mitomycin-C
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2011-01
- Completion
- 2016-02
- Enrolment
- 18
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPancreatic CancerInterventionIrinotecan; Cisplatin; Olaparib (for levels 1 and 5); Olaparib (for dose level 2) +1 morePhasePhase 1Registry statusCompletedAZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer
NCT01445418 · start 2008-05-12
Registered record
- Registry ID
- NCT01445418
- Conditions
- Breast Cancer; Ovarian Cancer
- Interventions
- AZ2281 + Carboplatin
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2008-05-12
- Completion
- 2019-10-18
- Enrolment
- 103
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBreast Cancer; Ovarian CancerInterventionAZ2281 + CarboplatinPhasePhase 1Registry statusCompletedAZD2281 and Irinotecan in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer
NCT00535353 · start 2008-01-02
Registered record
- Registry ID
- NCT00535353
- Conditions
- Colorectal Cancer
- Interventions
- irinotecan hydrochloride; olaparib
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2008-01-02
- Completion
- 2015-02-13
- Enrolment
- 26
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionColorectal CancerInterventionirinotecan hydrochloride; olaparibPhasePhase 1Registry statusCompletedA Study to Assess the Safety and Pharmacokinetics of an Inhibitor of Poly ADP-Ribose Polymerase-1 (PARP)
NCT00516373 · start 2005-07-11
Registered record
- Registry ID
- NCT00516373
- Conditions
- Ovarian Neoplasms; BRCA1 Protein; BRCA2 Protein
- Interventions
- KU-0059436 (AZD2281)(PARP inhibitor)
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2005-07-11
- Completion
- 2023-04-26
- Enrolment
- 98
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionOvarian Neoplasms; BRCA1 Protein; BRCA2 ProteinInterventionKU-0059436 (AZD2281)(PARP inhibitor)PhasePhase 1Registry statusCompleted